Fosmidomycin plus clindamycin for treatment of pediatric patients aged 1 to 14 years with Plasmodium falciparum malaria - Wikidata - wikimedia - TriplyDB

Fosmidomycin plus clindamycin for treatment of pediatric patients aged 1 to 14 years with Plasmodium falciparum malaria

Fosmidomycin plus clindamycin for treatment of pediatric patients aged 1 to 14 years with Plasmodium falciparum malaria

http://www.wikidata.org/entity/Q24680404

about

Assessment of the pharmacokinetics and dynamics of two combination regimens of fosmidomycin-clindamycin in patients with acute uncomplicated falciparum malaria The structure of Mycobacteria 2C-methyl-D-erythritol-2,4-cyclodiphosphate synthase, an essential enzyme, provides a platform for drug discovery Inhibition of 1-Deoxy- d -Xylulose-5-Phosphate Reductoisomerase by Lipophilic Phosphonates: SAR, QSAR, and Crystallographic Studies Molecular basis of fosmidomycin's action on the human malaria parasite Plasmodium falciparum Alteration of the Flexible Loop in 1-Deoxy- d -xylulose-5-phosphate Reductoisomerase Boosts Enthalpy-Driven Inhibition by Fosmidomycin Targeting an Aromatic Hotspot in Plasmodium falciparum 1-Deoxy-d-xylulose-5-phosphate Reductoisomerase with β-Arylpropyl Analogues of Fosmidomycin Experimental Genetics of Plasmodium berghei NFU in the Apicoplast Iron-Sulfur Cluster Biogenesis Pathway Fosmidomycin uptake into Plasmodium and Babesia-infected erythrocytes is facilitated by parasite-induced new permeability pathways Five questions about non-mevalonate isoprenoid biosynthesis Bioorganometallic mechanism of action, and inhibition, of IspH Deciphering the late biosynthetic steps of antimalarial compound FR-900098.Antimalarial compounds in Phase II clinical development.Sub-inhibitory fosmidomycin exposures elicits oxidative stress in Salmonella enterica serovar Typhimurium LT2.Resistance to the antimicrobial agent fosmidomycin and an FR900098 prodrug through mutations in the deoxyxylulose phosphate reductoisomerase gene (dxr).Randomized controlled trial of fosmidomycin-clindamycin versus sulfadoxine-pyrimethamine in the treatment of Plasmodium falciparum malaria Pharmacokinetics and pharmacodynamics of fosmidomycin monotherapy and combination therapy with clindamycin in the treatment of multidrug resistant falciparum malaria Inadequate efficacy of a new formulation of fosmidomycin-clindamycin combination in Mozambican children less than three years old with uncomplicated Plasmodium falciparum malaria.Thermodynamic Investigation of Inhibitor Binding to 1-Deoxy-D-Xylulose-5-Phosphate Reductoisomerase Plasmodium IspD (2-C-Methyl-D-erythritol 4-Phosphate Cytidyltransferase), an Essential and Druggable Antimalarial Target.Inhibition of IspH, a [4Fe-4S]2+ enzyme involved in the biosynthesis of isoprenoids via the methylerythritol phosphate pathway.Discovery of the antibiotic phosacetamycin via a new mass spectrometry-based method for phosphonic acid detection.Update on clindamycin in the management of bacterial, fungal and protozoal infections.FR-900098, an antimalarial development candidate that inhibits the non-mevalonate isoprenoid biosynthesis pathway, shows no evidence of acute toxicity and genotoxicity Biochemistry of the non-mevalonate isoprenoid pathway.Drug repositioning in the treatment of malaria and TB.Isoprenoid biosynthesis in the erythrocytic stages of Plasmodium falciparum.The isoprenoid-precursor dependence of Plasmodium spp.Emerging drugs for malaria.An in silico structural insights into Plasmodium LytB protein and its inhibition.Clinical pathologic conference case 5: agranulocytosis.Fosmidomycin as an antimalarial drug: a meta-analysis of clinical trials.Synthesis of functionalized cinnamaldehyde derivatives by an oxidative Heck reaction and their use as starting materials for preparation of Mycobacterium tuberculosis 1-deoxy-D-xylulose-5-phosphate reductoisomerase inhibitors.The apicoplast: now you see it, now you don't.Inhibition of the Fe(4)S(4)-cluster-containing protein IspH (LytB): electron paramagnetic resonance, metallacycles, and mechanisms.Pharmacodynamics of antimalarial chemotherapy.Improved efficacy of fosmidomycin against Plasmodium and Mycobacterium species by combination with the cell-penetrating peptide octaarginine.Biosynthesis of isoprenoids: studies on the mechanism of 2C-methyl-D-erythritol-4-phosphate synthase.Tropical medicine at the University of Tübingen.Drugs in Development for Malaria.

P2860

Q21034149-C47F0AFE-2B1E-4AB8-B57A-A6E286919936 Q27648874-2440B0E8-DC75-4DB2-A5E2-42B3F8520A66 Q27667791-7538E7F1-39E8-41D3-BC48-50C2AF0535AC Q27677409-5BF81C89-3247-4C00-B4CD-E096E1E11FD8 Q27683779-D5D9C37B-E2DE-402A-AFEA-2A46372B630C Q27724266-6C614BB9-6950-4817-A1D3-AF5177C78732 Q27972803-B07FB81D-0BC7-4EE5-A1F5-57F5DE6D3596 Q27974683-F1DAB304-B2C2-48E8-B1D9-3AB3BB0E309C Q28478574-FB99D604-D66A-4E80-8EC4-78A4302C8086 Q28748453-25EA95E0-D396-45BB-BBD4-881FB3940016 Q33645098-EE5BF064-8546-438D-8E5A-09A9361AACCA Q34456807-D600917E-CAB2-4C1D-80C9-42313A9E5A6D Q35153938-83F0ACBA-D0C3-4F74-907A-0E3062ECCD77 Q35678194-F7419C2B-77FE-437C-913D-66ED04D0B4B3 Q35759028-0F43F42C-6F5D-4F11-AD52-F05BA0F4A996 Q35850868-84D3255F-BF9D-44A4-AA52-C59DDBFD752D Q36018812-EBC0C66F-283C-4916-92C9-3D48ED066EA2 Q36290683-1D15D1C0-6D7D-41F8-93B9-22DBBE0B1382 Q36467783-5C17D160-11BD-4CA5-8BF4-DFBCD6D8D41F Q36817067-AD0122C7-4B1C-4FBF-BE6A-2C39BE058581 Q36853334-C3F23999-09CB-4399-9F67-3B2F14B8DE32 Q36967293-10AAA34A-7323-455A-866D-14A12B5E0D1D Q37189932-43394468-091F-4CEC-9F3E-6BFF9460F49C Q37899789-0688D3D4-8343-4B87-B985-6E43E5D5A1A2 Q37924298-69D3E847-0399-40D2-B7BB-111AA70610EA Q37924610-3A88F19E-A38C-425B-928B-866D8D0DF3E8 Q38007363-2CAE3508-B8B1-482F-8D2E-A807336890A1 Q38027179-48A811CA-DA10-4BE4-946F-74DE04693412 Q38396474-FD715E18-D0FD-4A82-A2E7-23D4C43DD738 Q38432599-69B8D0F2-1468-452A-9A6F-1FAC5CCA60C8 Q38558100-FD2794A2-595D-402A-9DB0-7B6590A4F7B6 Q38856166-B2FCEE7F-2492-4B06-BC9E-9B901EF9B41D Q38988845-B4FB0E63-3CCF-4201-A0F6-232A11659E21 Q40685503-187ACA23-1E95-4572-90EE-7D6EF5D07B7C Q41937695-5F451211-A2A5-4964-B703-C77BD4479740 Q42710241-CBBDE6B0-9D7D-4DC0-A528-EC7740790739 Q46491242-D886A361-57B5-47D8-94F9-70BBEE4E5661 Q47938411-836BD656-4246-4A6C-A9FE-FA41DE57A7B5 Q55278895-6CEFE56D-2B25-49EC-B858-6A1C73812E06

P2860

Fosmidomycin plus clindamycin for treatment of pediatric patients aged 1 to 14 years with Plasmodium falciparum malaria

http://www.wikidata.org/entity/Q24680404

description

2006 nî lūn-bûn

@nan

2006 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Fosmidomycin plus clindamycin ...... Plasmodium falciparum malaria

@ast

Fosmidomycin plus clindamycin ...... Plasmodium falciparum malaria

@en

Fosmidomycin plus clindamycin ...... Plasmodium falciparum malaria

@nl

type

label

Fosmidomycin plus clindamycin ...... Plasmodium falciparum malaria

@ast

Fosmidomycin plus clindamycin ...... Plasmodium falciparum malaria

@en

Fosmidomycin plus clindamycin ...... Plasmodium falciparum malaria

@nl

prefLabel

Fosmidomycin plus clindamycin ...... Plasmodium falciparum malaria

@ast

Fosmidomycin plus clindamycin ...... Plasmodium falciparum malaria

@en

Fosmidomycin plus clindamycin ...... Plasmodium falciparum malaria

@nl

P1433

Q24680404-E53D51C4-32D8-4392-B2FD-2B87A6AFE6FD

P1476

Q24680404-FC348B9D-527E-4192-AAFF-72D04F3DD4C9

P2093

Q24680404-0A105421-B679-4703-9D67-64624BEF9227

Q24680404-1A880FF5-5854-4024-84B3-949150520CD0

Q24680404-493E0BCC-E168-4A47-9ED9-F7342D276752

Q24680404-6563BA62-8C6C-40FB-9C1D-031FAC3ECDAE

Q24680404-AC52AAB4-6BC6-45B8-B38B-08C59587CF7E

Q24680404-C2FA6A80-78D1-4774-8EBA-061E97768FFD

Q24680404-D14BDDFB-0A01-4101-8242-F349177D0D92

Q24680404-FC9758B1-9964-473B-BFD2-BDCF64BDBCD0

Q24680404-FE915221-0987-4F62-B134-5D3C1CE4FFF6

P2860

Q24680404-0438E3E7-5A66-4169-9BC7-2EDD8D416CA0

Q24680404-06D5038B-2C05-43B2-A299-E0866B6CB46E

Q24680404-17317DDF-35AD-446B-8B9D-A84CE37A8392

Q24680404-1F087B60-F5B2-491C-BBCC-8204796986ED

Q24680404-25FADDB7-53AE-40C9-9472-89B48889BEE9

Q24680404-2C382D0F-CBAB-4EC5-8CA6-AB37854C720F

Q24680404-2CABAD06-6495-45A9-BA31-276AF0C8D940

Q24680404-347BB135-303A-45E2-B2FA-19FB28295AC1

Q24680404-3CD99255-E598-41D5-A98D-D293A87609A1

Q24680404-497B315F-0478-4BE9-9333-76F547068C59

P304

Q24680404-2F692E86-3AD3-477B-95D8-377EA046C8E3

P31

Q24680404-B7A7B69F-CFF2-4966-BCBB-E2A646291126

P356

Q24680404-C937A46F-A9FF-4987-BDE5-CFCE07D00E32

P407

Q24680404-2E520296-01F4-436E-9548-6179503FEC3C

P433

Q24680404-8F9605F3-E663-4E28-918D-6C84A0B96CA1

P478

Q24680404-FD163200-9D7D-4936-B494-973FBF072E15

P50

Q24680404-1B8CDE24-13B6-4BA9-BC90-136D05A55B24

Q24680404-284C3C59-BCC9-42CD-BBBF-170293C9235F

Q24680404-34D70BE8-0050-4A9E-B7E4-764E6869F3A3

P577

Q24680404-58208058-7E12-465F-BFF3-7C5915A074D3

P698

Q24680404-F562A659-3A26-4282-8A6D-BB5089DD6A4C

P921

Q24680404-073C08C9-6B95-409A-A07F-29272BA60710

Q24680404-7BEB2702-D145-4B87-8FB3-71B7D4AF2C82

P932

Q24680404-5529864C-42DA-4A13-BBD0-9E480564573D

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Fosmidomycin plus clindamycin ...... Plasmodium falciparum malaria

@en

P2093

Ayola A Adegnika

http://www.w3.org/2001/XMLSchema#string

Bénido Impouma

http://www.w3.org/2001/XMLSchema#string

David Hutchinson

http://www.w3.org/2001/XMLSchema#string

Hassan Jomaa

http://www.w3.org/2001/XMLSchema#string

Ingrid Lundgren

http://www.w3.org/2001/XMLSchema#string

Jochen Wiesner

http://www.w3.org/2001/XMLSchema#string

Jürgen F J Kun

http://www.w3.org/2001/XMLSchema#string

Pierre-Blaise Matsiegui

http://www.w3.org/2001/XMLSchema#string

Sunny Oyakhirome

http://www.w3.org/2001/XMLSchema#string

P2860

Clindamycin as an antimalarial drug: review of clinical trials.

Assessment of the pharmacodynamic properties of antimalarial drugs in vivo

Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs

Estimating mortality, morbidity and disability due to malaria among Africa's non-pregnant population.

Short-course regimens of artesunate-fosmidomycin in treatment of uncomplicated Plasmodium falciparum malaria.

In vitro and in vivo synergy of fosmidomycin, a novel antimalarial drug, with clindamycin.

Fosmidomycin-clindamycin for Plasmodium falciparum Infections in African children.

Fosmidomycin, a novel chemotherapeutic agent for malaria.

Fosmidomycin for the treatment of malaria.

Effects of amodiaquine, chloroquine, and mefloquine on human polymorphonuclear neutrophil function in vitro.

P304

2713-8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.00392-06

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

50

http://www.w3.org/2001/XMLSchema#string

P50

Steffen Borrmann

Peter Gottfried Kremsner

P577

2006-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16870763

http://www.w3.org/2001/XMLSchema#string

P921

Plasmodium falciparum

P932

1538678

http://www.w3.org/2001/XMLSchema#string